Last reviewed · How we verify
HCP1904-1
HCP1904-1 is a selective androgen receptor degrader (SARD) that binds to and promotes degradation of the androgen receptor protein.
HCP1904-1 is a selective androgen receptor degrader (SARD) that binds to and promotes degradation of the androgen receptor protein. Used for Castration-resistant prostate cancer (CRPC), Hormone-sensitive prostate cancer.
At a glance
| Generic name | HCP1904-1 |
|---|---|
| Sponsor | Hanmi Pharmaceutical Company Limited |
| Drug class | Androgen receptor degrader (SARD) |
| Target | Androgen receptor (AR) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
By inducing proteasomal degradation of the androgen receptor rather than simply blocking its activity, HCP1904-1 eliminates both the full-length receptor and constitutively active truncated variants that can drive treatment-resistant disease. This mechanism is designed to overcome resistance mechanisms seen with traditional androgen receptor antagonists in hormone-sensitive and castration-resistant prostate cancer.
Approved indications
- Castration-resistant prostate cancer (CRPC)
- Hormone-sensitive prostate cancer
Common side effects
- Fatigue
- Nausea
- Diarrhea
- Rash
Key clinical trials
- A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of HCP1904 in Healthy Male Volunteers. (PHASE1)
- A Study to Evaluate the PK, Safety and Tolerability of HCP1803. (PHASE1)
- Clinical Efficacy and Safety Evaluation of HCP1904-1 in Essential Hypertension Patients (PHASE3)
- A Study to Compare the Pharmacokinetics, Safety and Tolerability Between Fixed-Dose Combination of HCP1904 and Co-Administration of RLD2001-2 and RLD2006 Tablets in Healthy Subjects. (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HCP1904-1 CI brief — competitive landscape report
- HCP1904-1 updates RSS · CI watch RSS
- Hanmi Pharmaceutical Company Limited portfolio CI